Ryerson, Lana Zhovtis et al "Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988)." Neurology 94.15 Supplement (2020): 1988. Web. 02 Dec. 2020.